TARSUS PHARMACEUTICALS, INC. (TARS) Return on equity 2020–2025
TARSUS PHARMACEUTICALS, INC. (TARS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-19.3%FY2025 · since FY2020: -16.2% → -19.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -19.3% | +32.1 pp |
| FY2024 | -51.5% | +17.5 pp |
| FY2023 | -69.0% | -36.8 pp |
| FY2022 | -32.2% | -23.9 pp |
| FY2021 | -8.3% | +7.9 pp |
| FY2020 | -16.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TARS financial trends
TARS RevenueTARS Net incomeTARS Net marginTARS Gross profitTARS Gross marginTARS Operating incomeTARS Operating marginTARS Operating cash flowTARS Free cash flowTARS Capital expendituresTARS Stock buybacksTARS Dividends paidTARS Total assetsTARS Total liabilitiesTARS Shareholders’ equityTARS overview →